

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 2120

VOLUNTARY ANNOUNCEMENT PRINCIPAL OPERATING DATA AND INDICATORS FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND THE SECOND QUARTER 2022

This is a voluntary announcement made by Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The table below sets forth the relevant operating data and indicators of the Group’s owned hospitals by inpatients and outpatients for the six months ended June 30, 2022 with comparative figures for the six months ended June 30, 2021:

	For the six months ended June 30,		
	2022	2021	Year-on-year changes
Inpatients			
Number of inpatient bed-days	1,505,499	1,315,493	14.4%
Average inpatient spending per bed-day on treatment and general healthcare services (RMB)	338	324	4.3%
Average inpatient spending per bed-day on pharmaceutical sales (RMB)	50	55	-9.1%
Total average inpatient spending per bed-day (RMB)	388	379	2.4%
Outpatients			
Number of outpatient visits (Note)	225,032	167,576	34.3%
Average outpatient spending per visit on treatment and general healthcare services (RMB) (Note)	118	127	-7.1%
Average outpatient spending per visit on pharmaceutical sales (RMB)	323	335	-3.6%
Total average outpatient spending per visit (RMB)	441	462	-4.3%

The table below sets forth the relevant operating data and indicators of the Group's owned hospital by inpatients and outpatients for the three months (the second quarter) from April 1, 2022 to June 30, 2022 with comparative figures of the same period in 2021:

	Three months from April 1 to June 30,		
	2022	2021	Year-on-year changes
Inpatients			
Number of inpatient bed-days	786,633	705,626	11.5%
Average inpatient spending per bed-day on treatment and general healthcare services (<i>RMB</i>)	337	327	3.1%
Average inpatient spending per bed-day on pharmaceutical sales (<i>RMB</i>)	50	53	-5.7%
Total average inpatient spending per bed-day (<i>RMB</i>)	387	380	1.8%
Outpatients			
Number of outpatient visits (<i>Note</i>)	112,752	95,430	18.2%
Average outpatient spending per visit on treatment and general healthcare services (<i>RMB</i>) (<i>Note</i>)	123	119	3.4%
Average outpatient spending per visit on pharmaceutical sales (<i>RMB</i>)	330	303	8.9%
Total average outpatient spending per visit (<i>RMB</i>)	453	421	7.6%

The above operating data are based on the Company's records and have not been audited or reviewed by the Company's auditors. The operating data may be different from those disclosed in periodical reports. The operating data disclosed in periodical reports shall prevail if there is any discrepancy. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: The above data of number of outpatient visits and average outpatient spending per visit on treatment and general healthcare services are excluding the business of the COVID-19 nucleic acid test.

CONTINUED TRADING SUSPENSION

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on April 1, 2022. Trading in the shares of the Company will remain suspended until further notice.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC
 July 4, 2022

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Mr. ZHAO Xudong, Ms. ZHONG Wentang and Mr. LIU Ning.